Correspondingly, in an earlier in vivo study, it was demonstrated that the L165, 041 PPAR-δ agonist was superior to the F-L-Leu PPAR-γ agonist for treating the i.c. STZ model of AD-type neurodegeneration [28]. This evidence concerns the gene PPARG and Alzheimer disease.